<DOC>
	<DOCNO>NCT01082276</DOCNO>
	<brief_summary>The effect rifampin pharmacokinetics lurasidone</brief_summary>
	<brief_title>Rifampin Drug-Drug Interaction Study With Lurasidone HCl</brief_title>
	<detailed_description>perform open-label , 2-period , sequential study healthy subject . All subject ( N=20 ) assign treatment sequence , 40 mg po dosing .</detailed_description>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>1 . Female subject must nonchildbearing potential ( surgically sterile [ hysterectomy bilateral tubal ligation ] postmenopausal â‰¥ 1 year ) follicle stimulate hormone [ FSH ] &gt; 40 U/L ) . 2 . Subjects partner childbearing potential must agree use barrier contraception study 90 day discharge . Volunteers must agree donate sperm study 90 day discharge . 1 . Any disorder would interfere absorption , distribution , metabolism , excretion drug . 2 . Use concomitant medication prolong QT/QTc interval 14 day prior day 2 discharge . 3 . Use inhibitor inducer CYP3A4 take within 30 day prior study Day 2 4 . Use ( ) investigational drug ( ) within 30 day 5 halflives ( whichever longer ) prior Screening . 5 . Previous exposure lurasidone ( SM13496 ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Rifampin DDI Lurasidone HCl</keyword>
</DOC>